FDA-Approved Therapy
UPMC Hillman Cancer Center currently offers all FDA-approved CAR T-cell therapies.
Learn MoreUPMC Hillman Cancer Center is part of the UPMC family.
Starting Feb. 29, masking is optional but encouraged in UPMC medical facilities and most patient care settings.
Explore this Section
Chimeric antigen receptor (CAR) T-cell therapy uses a person's own T cells to find and kill cancer cells.
UPMC Hillman Cancer Center was one of the first centers in the U.S. to offer CAR T-cell immunotherapy.
UPMC also tests new forms of this cutting-edge cancer treatment through clinical trials.
To learn if a CAR-T cell clinical trial is right for you, call 1-833-876-2227.
A T cell is a type of white blood cell that fights infection and disease. When a T cell sees a threat — like a virus-infected cell — it kills that cell to protect the body.
The goal of CAR T-cell therapy is to make T cells attack cancer cells instead of just infected cells.
First, doctors harvest a person's T cells and send them to a special lab. The lab genetically alters the cells to spot a certain protein in cancer cells. They then grow large numbers of the altered T cells.
After a few weeks in the lab, the CAR T cells will be ready for infusion.
Once the CAR T cells return to UPMC, our team puts them back into the person. The CAR T cells then attack and kill cancer cells as they were “trained."
CAR T-cell therapy is challenging to provide, so few hospitals can offer this potentially lifesaving treatment.
UPMC Hillman Cancer Center:
To refer a patient for evaluation for one of these clinical trials, please call 1-833-876-2227.
If you think you might be a candidate for one of these clinical trials, please call 1-833-876-2227.
FDA-Approved Therapy
UPMC Hillman Cancer Center currently offers all FDA-approved CAR T-cell therapies.
Learn MoreResearch and Clinical Trials
UPMC Hillman Cancer Center is currently enrolling patients in CAR T-cell therapy clinical trials.
Learn More